Columbia Trust Co 01012016 Raises Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Columbia Trust Co 01012016 grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 14.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,911 shares of the medical equipment provider’s stock after purchasing an additional 363 shares during the quarter. Columbia Trust Co 01012016’s holdings in Intuitive Surgical were worth $982,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ISRG. Blair William & Co. IL lifted its stake in Intuitive Surgical by 3.1% in the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after acquiring an additional 11,400 shares during the period. Assenagon Asset Management S.A. lifted its stake in Intuitive Surgical by 21.2% in the third quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock worth $216,140,000 after acquiring an additional 129,194 shares during the period. Falcon Wealth Planning purchased a new stake in Intuitive Surgical in the fourth quarter worth about $2,084,000. AMF Tjanstepension AB lifted its stake in Intuitive Surgical by 637.3% in the third quarter. AMF Tjanstepension AB now owns 127,624 shares of the medical equipment provider’s stock worth $37,303,000 after acquiring an additional 110,314 shares during the period. Finally, Banque Pictet & Cie SA lifted its stake in Intuitive Surgical by 7.7% in the third quarter. Banque Pictet & Cie SA now owns 72,085 shares of the medical equipment provider’s stock worth $21,070,000 after acquiring an additional 5,151 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded up $5.92 during midday trading on Tuesday, hitting $397.63. The company’s stock had a trading volume of 1,542,986 shares, compared to its average volume of 1,688,377. Intuitive Surgical, Inc. has a fifty-two week low of $246.63 and a fifty-two week high of $403.00. The firm has a market cap of $140.94 billion, a P/E ratio of 79.05, a P/E/G ratio of 6.12 and a beta of 1.36. The firm’s 50 day moving average is $383.66 and its 200-day moving average is $331.65.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The company had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same period last year, the firm posted $0.91 EPS. Intuitive Surgical’s revenue for the quarter was up 16.6% compared to the same quarter last year. As a group, analysts forecast that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of research reports. Morgan Stanley upped their price objective on shares of Intuitive Surgical from $300.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. Raymond James upped their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Stifel Nicolaus reissued a “buy” rating and set a $420.00 price target on shares of Intuitive Surgical in a research report on Friday, March 15th. Truist Financial increased their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Finally, Piper Sandler increased their price target on shares of Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $371.60.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the transaction, the vice president now directly owns 110 shares of the company’s stock, valued at approximately $43,677.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the transaction, the vice president now directly owns 110 shares of the company’s stock, valued at approximately $43,677.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 329 shares of Intuitive Surgical stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $390.16, for a total transaction of $128,362.64. Following the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,148,611.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 248,418 shares of company stock valued at $95,927,097. 0.80% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.